HANGZHOU, China, July 5, 2024
/PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a
clinical stage biopharmaceutical company developing innovative
biotherapeutics for metabolic diseases and cancers, today announces
that the company has completed the enrollment in the Phase
1b/2a trial evaluating DR10624 in
obese subjects with modest hypertriglyceridemia in New Zealand. DR10624 is a first-in-class
(FIC), long-acting tri-specific agonist targeting Fibroblast growth
factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor
(GLP-1R), and Glucagon receptor (GCGR).
The Phase 1b/2a study is a
randomized, placebo-controlled, double-blind study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynamics of
DR10624 in adult obese subjects (BMI of 30 to 45 kg/m2)
with modest hypertriglyceridemia (fasting triglyceride ≥150 mg/dL
(1.7 mmol/L), and <500 mg/dL (5.7 mmol/L), at screening). The
study evaluates DR10624 treatment across four different dose
levels. The participants will receive once-weekly subcutaneous
injection of DR10624 or placebo (in a 10:2 ratio) for 12 weeks. The
study will also evaluate the effects of DR10624 on serum lipids,
liver fat, and body weight.
"DR10624 is a novel FIC tri-specific biotherapeutic that
specifically agonizing FGF21R, GLP-1R, and GCGR. Utilizing Doer
Bio's proprietary MultipleBody® platform technology,
DR10624 is designed and engineered to exhibit balanced activity for
various metabolic diseases. In our preclinical studies, DR10624 has
shown outstanding potency on body weight reduction, blood lipid
normalization, and liver function improvement." said Yanshan Huang, Ph.D., founder and Chief
Executive Officer of Doer Bio.
"We're excited to announce the successful completion of patient
enrollment for our Phase 1b/2a
clinical trial of DR10624 in New
Zealand. This achievement marks an important milestone in
our clinical translation of DR10624 globally. We anticipate
reporting the trial results in early 2025. There is a growing unmet
medical need for patients suffering from obesity and
hypertriglyceridemia. We look forward to developing DR10624 as a
potential treatment for patients struggling with metabolic
dysfunction." commented
Yongliang Fang, Ph.D., Chief
Operating Officer of Doer Bio.
More information about the Phase 1b/2a clinical trial is available at
clinicaltrials.gov (NCT05378893)
About Doer Bio
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical
stage biopharmaceutical company that focuses on the discovery and
development of multi-domain based multi-specific biotherapeutics to
address unmet medical need in the field of metabolic diseases and
cancers.
Doer Bio has developed multiple proprietary platform
technologies, including xLONGylation®,
MultiBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Bio, please visit
www.doerbio.com.
CONTACT: bd@doerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zhejiang-doer-biologics-completes-enrollment-of-the-phase-1b2a-trial-evaluating-dr10624-in-obese-subjects-with-modest-hypertriglyceridemia-302189900.html
SOURCE Zhejiang Doer Biologics Co., Ltd.